Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/ijmr.IJMR_3665_20 http://scihub22266oqcxt.onion/10.4103/ijmr.IJMR_3665_20 33818472!8184066!33818472     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Indian+J+Med+Res 2021 ; 153 (1 & 2): 151-158 Nephropedia Template TP {{tp|p=33818472|t=2021. Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial |pdf=|usr=}}{{33818472}} gab.com Text Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial JO: Indian J Med Res http://www.kidney.de/pget.php?&tw=1&pmid=33818472 #FOAvip BACKGROUND & OBJECTIVES: Chloroquine (CQN) administered as nasal drops has the potential to achieve much greater local tissue levels than with oral/systemic administration. This trial was undertaken to study the efficacy and safety profile of topical nasal administration of CQN drops in reducing viral load and preventing clinical progression in early COVID-19 infection. METHODS: This randomized clinical trial was done with a sample size of 60. Reverse transcription-polymerase chain reaction (RT-PCR) confirmed asymptomatic patients or those with mild COVID-19 illness [National Early Warning Score (NEWS) </=4] were included. Patients were randomized in a 1:1 manner. Control arm (standard supportive treatment, n=30) was compared with intervention arm (n=30) of standard treatment plus CQN eye drops (0.03%) repurposed as nasal drops administered six times daily (0.5 ml/dose) for 10 days. Outcome measures were adverse events and adherence; clinical progression and outcomes were measured by NEWS; sequential RT-PCR cycle threshold (Ct) values were also noted on days 0, 3, 7 and 10. RESULTS: Nasal CQN was associated with local irritation in seven and non-compliance in one of 30 patients. Eleven patients were excluded due to enrolment error (2 - recovered; 9 - false-positive referral), and 49 patients were analyzed as per modified intention-to-treat analysis. Clinical recovery was noted as similar with 100 per cent asymptomatic by day seven in both arms. Virological outcomes also indicated similarly improving Ct values in both arms, and similar proportion of patients transitioning to non-infectivity by day 10 (controls - 19/25; nasal CQN - 15/24). Nine false-positive patients with enrolment error and day 0 RT-PCR negative were initially uninfected but had continuing COVID-19 exposure and treatment as per randomization. Patients receiving nasal CQN (n=5) demonstrated stable Ct values from day 0 to 10, while patients with no nasal CQN (n=4) demonstrated significant dip in Ct value indicating to infection (Ct<35) and infectivity (Ct<33). INTERPRETATION & CONCLUSIONS: The present study suggests to the potential of topical nasal CQN in the prevention of COVID-19 infection if administered before the infection is established. No significant differences in clinical or virological outcome were however, demonstrated in patients with mild but established illness. Twit Text FOAVip Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial ????Indian J Med Res http://www.kidney.de/pget.php?&tw=1&pmid=33818472 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33818472 #FOAvip English Wikipedia <ref>{{Cite pmid|33818472}}</ref> Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial #MMPMID33818472 Thakar A; Panda S; Sakthivel P; Brijwal M; Dhakad S; Choudekar A; Kanodia A; Bhatnagar S; Mohan A; Maulik SK; Dar L Indian J Med Res 2021[Jan]; 153 (1 & 2): 151-158 PMID33818472show ga BACKGROUND & OBJECTIVES: Chloroquine (CQN) administered as nasal drops has the potential to achieve much greater local tissue levels than with oral/systemic administration. This trial was undertaken to study the efficacy and safety profile of topical nasal administration of CQN drops in reducing viral load and preventing clinical progression in early COVID-19 infection. METHODS: This randomized clinical trial was done with a sample size of 60. Reverse transcription-polymerase chain reaction (RT-PCR) confirmed asymptomatic patients or those with mild COVID-19 illness [National Early Warning Score (NEWS) |*Administration, Intranasal[MESH] |*COVID-19 Drug Treatment[MESH] |Chloroquine/*therapeutic use[MESH] |Humans[MESH]Chloroquine nasal drops in asymptomatic & mild COVID-19: An explorator(epmc).pdf DeepDyve Pubget Overpricing